Trial Profile
A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary) ; Bupropion; Warfarin
- Indications Adenocarcinoma; Basal cell cancer; Carcinoid tumour; Carcinoma; Cholangiocarcinoma; Liver cancer; Malignant melanoma; Neuroendocrine carcinoma; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 31 Jul 2020 Results published in the British Journal of Clinical Pharmacology.
- 15 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.